Clinicians at CHEST 2026 will see late-breaking COPD, asthma, pulmonary hypertension, and bronchoscopy data, plus exclusive expert interviews.
News|Articles|October 19, 2026
CHEST 2026: Day 1 Recap — 5 Headlines to Know
Author(s)Chelsie Derman
Fact checked by: Victoria Johnson
Check out highlights from news published on day 1 of CHEST 2026, spanning asthma, COPD, bronchiectasis, pulmonary rehabilitation, and fibrotic ILD.
Advertisement
Advertisement
Day 1 of the
Related to this article
In pooled phase 3 data, mepolizumab lowered mean yearly systemic corticosteroid exposure by 178.97 mg in patients with a BEC of ≥150 cells/µL.
Chronic proton pump inhibitor use carried 60% greater odds of asthma exacerbation and nearly 4-fold odds of rescue corticosteroid use in a matched cohort of 2456 patients.
George Washko, MD, discusses a late-breaking OBERON/TITANIA analysis showing tozorakimab reduces segmental mucus plug scores in COPD.
Advanced practice providers described how documentation, specialty pharmacy support, and payer requirements shape biologic selection and timing.
Participants said payer criteria and patient goals often outweigh mechanism when choosing biologics, and that shared decision-making is harder in COPD.
Participants described how comorbidities, payer formularies, and patient preference shape biologic choice in asthma and COPD.
Repeated oral steroid bursts are the main trigger for starting a biologic, while therapy for non-type 2 inflammation COPD remains an unmet need.
Advertisement
Advertisement